Heart Concerns Shift To Aleve Following Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary data suggest long-term naproxen use caused a 50% increase in cardiovascular adverse events compared to placebo in a prematurely halted trial, which also included Pfizer's COX-2 inhibitor Celebrex (celecoxib)
You may also be interested in...
Trial Registries Would Boost Public Trust In Clinical Studies – Survey
Two-thirds of Americans queried in a December 2004 survey believe clinical trials are safe for participants, the Center for Information & Study on Clinical Research Participation reports. More than half of respondents said a public database of clinical trial results would boost their trust in such studies.
Trial Registries Would Boost Public Trust In Clinical Studies – Survey
Two-thirds of Americans queried in a December 2004 survey believe clinical trials are safe for participants, the Center for Information & Study on Clinical Research Participation reports. More than half of respondents said a public database of clinical trial results would boost their trust in such studies.
Celebrex, Bextra Given Breathing Room In Latest FDA Advisory
Agency suggests any regulatory action on COX-2s or non-selective NSAIDs will wait until after a February advisory committee meeting. A public health advisory urges physicians to consider the “emerging” information on cardiovascular risk when prescribing COX-2s. FDA also orders a review of all prevention studies using Pfizer’s Celebrex and Bextra.